Literature DB >> 34817048

COVID-19 and strongyloidiasis: what to expect from this coinfection?

Carolina Victoria Marcitelli Pereira1, Giovanna Ribeiro Achur Mastandrea1, Ana Clara Cassine de Souza Medeiros1, Ronaldo Cesar Borges Gryschek2,3, Fabiana Martins de Paula2,3, Marcelo Andreetta Corral1,2,3.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34817048      PMCID： PMC8579849          DOI： 10.6061/clinics/2021/e3528

Source DB:  PubMed          Journal:  Clinics (Sao Paulo)        ISSN： 1807-5932            Impact factor:   2.365


× No keyword cloud information.
  15 in total

Review 1.  Epidemiological aspects of strongyloidiasis in Brazil.

Authors:  F M Paula; J M Costa-Cruz
Journal:  Parasitology       Date:  2011-08-03       Impact factor: 3.234

Review 2.  Diagnosis of human strongyloidiasis: Application in clinical practice.

Authors:  Idessania Nazareth Costa; Larissa Rodrigues Bosqui; Marcelo Andreetta Corral; Julia Maria Costa-Cruz; Ronaldo César Borges Gryschek; Fabiana Martins de Paula
Journal:  Acta Trop       Date:  2021-08-05       Impact factor: 3.112

3.  COVID-19 and Dexamethasone: A Potential Strategy to Avoid Steroid-Related Strongyloides Hyperinfection.

Authors:  William M Stauffer; Jonathan D Alpern; Patricia F Walker
Journal:  JAMA       Date:  2020-08-18       Impact factor: 56.272

4.  Neglected tropical diseases in non-endemic countries in the era of COVID-19 pandemic: the great forgotten.

Authors:  Marta Tilli; Piero Olliaro; Federico Gobbi; Zeno Bisoffi; Alessandro Bartoloni; Lorenzo Zammarchi
Journal:  J Travel Med       Date:  2021-01-06       Impact factor: 8.490

5.  Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin.

Authors:  Francisco M Marty; Colleen M Lowry; Martin Rodriguez; Danny A Milner; Walter S Pieciak; Anushua Sinha; Lawrence Fleckenstein; Lindsey R Baden
Journal:  Clin Infect Dis       Date:  2005-05-11       Impact factor: 9.079

6.  [Reactivation of Strongyloides stercoralis in patients with SARS-CoV-2 pneumonia receiving dexamethasone].

Authors:  Lucia Feria; Missia Torrado; Vanesa Anton-Vazquez
Journal:  Med Clin (Barc)       Date:  2021-05-27       Impact factor: 1.725

7.  Corticosteroids in Covid-19 pandemic have the potential to unearth hidden burden of strongyloidiasis.

Authors:  Disha Gautam; Ayush Gupta; Adarsh Meher; Farha Siddiqui; Abhishek Singhai
Journal:  IDCases       Date:  2021-06-12

8.  Dexamethasone and COVID-19: Strategies in Low- and Middle-Income Countries to Tackle Steroid-Related Strongyloides Hyperinfection.

Authors:  Mario J Olivera
Journal:  Am J Trop Med Hyg       Date:  2021-03-15       Impact factor: 2.345

Review 9.  Prevalence of strongyloidiasis in Latin America: a systematic review of the literature.

Authors:  D Buonfrate; M A Mena; A Angheben; A Requena-Mendez; J Muñoz; F Gobbi; M Albonico; E Gotuzzo; Z Bisoffi
Journal:  Epidemiol Infect       Date:  2014-07-03       Impact factor: 4.434
View more
  2 in total

1.  Evaluation of Strongyloides Awareness and Knowledge among Canadian Physicians Caring for Patients At Risk for Severe Strongyloidiasis: A National Cross-sectional Survey.

Authors:  Samuel De l'Étoile-Morel; Faheel Naeem; Mohammad Alghounaim; Makeda Semret; Cedric P Yansouni; Michael D Libman; Sapha Barkati
Journal:  Am J Trop Med Hyg       Date:  2022-07-05       Impact factor: 3.707

2.  Strongyloides Hyperinfection Syndrome among COVID-19 Patients Treated with Corticosteroids.

Authors:  Jani M Kim; Geetha Sivasubramanian
Journal:  Emerg Infect Dis       Date:  2022-07       Impact factor: 16.126
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.